Qiagen Completes Non-US Offering of Convertible Notes to Raise up to $300M | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday that it successfully completed the previously announced repurchase of convertible notes due in 2026 and the issuance of new convertible notes due in 2019 and 2021.

The transactions are anticipated to raise $300 million in net proceeds, to be used for general corporate purposes, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.